News - ANAVEX

View all Alzheimer's Disease Anavex2-73 Events News Releases PIPELINE Press Uncategorized

Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients Presented at AAIC 2016

Anavex Presents 31-Week Efficacy Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients at AAIC 2016

Anavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients at AAIC 2016

Anavex to Present at the Alzheimer’s Association International Conference (AAIC) 2016

Alzheimer’s Association International Conference 2016 (AAIC) – July 24, 2016

Alzheimer’s Association International Conference 2016 (AAIC) – July 27, 2016

Anavex to Present at the 2016 Rett Syndrome Symposium

Anavex Announces U.S. FDA Orphan Drug Designation for ANAVEX 2-73 for Treatment of Infantile Spasms

ANAVEX 2‐73 as a Potential Treatment for Rett Syndrome and Other Pediatric or Infantile Disorders with Seizure Pathology.

2016 Rett Syndrome Symposium